Answers are grounded in this paper and cite their sources.
Simulations presented here for the first time suggest that rebinding may increase the duration and even the constancy of the drug's clinical action. Intact cell radioligand dissociation and related ex vivo experiments offer useful indications about a drug's aptitude to experience target rebinding.
No takes yet. Share an insight, caveat, or question.
Georges Vauquelin (2010) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: